KCT0002899
Recruiting
未知
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients With Castration-Resistant Prostate Cancer with Osseous Metastases
Korea Cancer Center Hospital0 sites20 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Korea Cancer Center Hospital
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically diagnosed prostate cancer patient
- •\- previous surgical or chemical castration with serum testosterone \<50 ng / dL
- •\- Persons who continue to use LHRH agonists during clinical trials if the castration method is a luteinizing hormone\-releasing hormone (LHRH) agonist.
- •\- Prostate Serum Antigen (PSA) \= 5 ng / mL
- •\- Clinically diagnosed with castration\-resistant prostate cancer
- •\- Those with radiographic evidence of at least two measurable bone metastases (radionuclide bone scan, CT scan or MRI)
- •2\. Able to provide informed consent and have signed an approved consent form that conforms to institutional guidelines to ensure compliance
- •3\. Men with age \=/\> 19 years and \=/\<80 years
- •4\. ECOG \_ Performance scale \=2
- •5\. Life expectancy of greater than or equal to 6 months.
Exclusion Criteria
- •1\. A person who is judged to be difficult to perform a clinical trial due to a serious medical condition
- •2\. Visceral metastases as assessed
- •3\. Lymphadenopathy exceeding 3 cm in short\-axis diameter
- •4\. The person who is determined to have a mental disorder that is difficult to perform PET (Positron Emission Tomography) scan
- •5\. Those participating in other clinical trials at screening and participating in clinical trials should be able to influence the acquisition of 18F\-fluorodeoxyglucose or 18F\-NaF PET images (For example, if you are participating in another cohort\-based trial that is simply focused on monitoring that you do not receive medicines during screening, you can participate in the current clinical trials.)
- •6\. Those who participated in other clinical trials that may affect the acquisition of 18F\-FDG or 18F\-NaF PET (Positron Emission Tomography) images from the time of registration until the end of the study, or that may affect the safety assessment following intravenous injection of 223Ra dichloride
- •7\. Those who are likely to influence the acquisition of 18F\-fluorodeoxyglucose PET (Positron Emission Tomography) imaging due to unadjusted diabetes
- •8\. Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
- •9\. Vulnerable subjects (researchers or students who participated in research, family members, researchers or students of researchers participating in research)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients With Locally Recurrent of Metastatic OsteosarcomaKCT0002905Korea Cancer Center Hospital20
Recruiting
Not Applicable
Changes in 18F-NaF PET/CT and 18F-FDG PET/CT after 223Ra Dichloride Treatment in Patients with Breast Cancer with Osseous MetastasesKCT0002909Korea Cancer Center Hospital20
Completed
Not Applicable
The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomyBladder cancerJPRN-UMIN000043722Al Zahraa Hospital300
Recruiting
Phase 3
18F-fluciclovine PET/CT and 18F-DCFPyL PET/CT in patients with biochemical recurrence of disease after radical prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.malignancy of the prostateProstate cancer10036958NL-OMON50844Vrije Universiteit Medisch Centrum50
Active, not recruiting
Phase 1
A prospective imaging study with 18F-fluciclovine PET/CT and 18F-DCFPyL in patients with biochemical reccurence of prostate cancer.EUCTR2021-001123-40-NLAmsterdam UMC, VU University Medical Center50